Universal Chimeric Antigen Receptor T-Cell Immunotherapy(Calmhome Cell and Gene Engineering Institute)

N/A

Report date: 2025/11/27 14:36:52

Base Information

Drug NameUniversal Chimeric Antigen Receptor T-Cell Immunotherapy(Calmhome Cell and Gene Engineering Institute)
Drug Alias NameCHT102CHT-102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-MesothelinT lymphocyte replacements
TargetsMesothelin
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesTianjin Medical University Cancer Institute And HospitalNanjing Calmhome Cell and Gene Engineering Institute Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Miracle Pharmaceutical Biotechnology Co., Ltd.Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A